Why the study?
With the expanding role of DOACs, clinicians face increasingly complex decisions regarding agent selection, treatment duration, and use in special populations.
How can clinicians optimize the use of direct oral anticoagulants (DOACs) in common challenging clinical scenarios?
How can clinicians optimize the use of direct oral anticoagulants (DOACs) in common challenging clinical scenarios?
This review serves as a practical reference for clinicians to optimize the use of direct oral anticoagulants across various challenging clinical scenarios.
May guide DOAC optimization in complex cases; leaves open need for updated prospective validation.
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios. Topics addressed include (1) appropriate indications; (2) use in patients with specific comorbidities; (3) monitoring parameters; (4) transitioning between anticoagulant regimens; (5) major drug interactions; and (6) cost considerations.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: